Date: August 13, 2026
Ref. No.: KDL/SE/027/2026-27

To,	To,
BSE Limited	**National Stock Exchange of India Limited**
Corporate Relationship Department	Exchange Plaza, Plot No. C-1, Block G,
25th Floor, Phiroze Jeejeebhoy Towers	Bandra Kurla Complex, Bandra (East)
Dalal Street, Mumbai- 400001	Mumbai – 400051
Scrip Code: 543328	**NSE Symbol:** KRSNAA

Subject: Outcome of Board Meeting held on August 13, 2026.

In compliance with Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with Schedule III of aforesaid regulation and SEBI Circular No. SEBI HO/49/14/14(7) 2025-CFD-POD2/I/3762/2026 dated January 30, 2026 we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. August 13, 2026, has discussed and approved the following items:

a. Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2026 along with the Limited Review Reports as issued by the statutory auditors of the Company, enclosed as Annexure –A;

b. Director's report along with all the Annexures forming part of the Annual report of the company for the financial year 2025-26;

c. Notice of the 16th AGM of the Company which would be held on Monday, September 28, 2026 at 11:00 Hrs. (IST) through in Physical Mode, inter-alia, to transact the business as set out in the said Notice.

Sr. No.	Particulars	Remarks
1	Date and Time of AGM	Monday, September 28, 2026 at 11:00 Hrs. (IST)
2	Mode of Meeting as per Regulatory Requirement	Physical Mode
3	Record date for Payment of Final Dividend	Friday, September 18, 2026
4	Book Closure Date	From: Saturday, September 19, 2026 To: Monday, September 28, 2026 (Both Days inclusive)
5	Dividend Declared by Board	May 25, 2026
6	Final Dividend recommended for F.Y. 2024-25	INR 2.00/- (Rupees Two only)
7	Contact details of the Company	Mr. Sujoy Sudipta Bose Company Secretary and Compliance Officer Email ID: investors@krsnaa.in Contact No.: (+91) 20 27402400

RS

d. The issuance of 16,21,000 share warrants to Mr. Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited (Promoter and Promoter Group) up at an issue price determined in future, which would be higher of the following:
   - The floor price as on the relevant date in the future as determined in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 or;
   - Rs. 565/-.

The Board Meeting commenced at 13:30 Hrs. (IST) and concluded at 21:00 Hrs. (IST)

Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited

Sujoy Sudipta Bose

Digitally signed by Sujoy Sudipta Bose
Date: 2026.08.13 23:02:58 +05'30'

Krsnaa Diagnostics Limited

Sujoy Sudipta Bose
Company Secretary and Compliance Officer
Encl: As above

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

Floor 6, Building No. 1
Cerebrum IT Park, Kalyani Nagar
Pune 411014, INDIA

Independent Auditor's Review Report on consolidated unaudited financial results of Krsnaa Diagnostics Limited for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Krsnaa Diagnostics Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Krsnaa Diagnostics Limited (hereinafter referred to as 'the Holding Company') , its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') and its share of the net profit after tax and total comprehensive income of its associate for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entity(ies): (indicate list of entities included in the consolidation)

Sr. No	Name of the Entity	Relationship with the Holding Company
1.	KRSNAA DIAGNOSTICS (MOHALI) PRIVATE LIMITED	Wholly Owned Subsidiary
2.	KDPL DIAGNOSTICS (AMRITSAR) PRIVATE LIMITED	Wholly Owned Subsidiary
3.	KDPL DIAGNOSTICS (BATHINDA) PRIVATE LIMITED	Wholly Owned Subsidiary
4.	KDPL DIAGNOSTICS (JALANDHAR) PRIVATE LIMITED	Wholly Owned Subsidiary

MSKA & ASSOCIATES LLP ★ Chartered Accountants ★

5.	KDPL DIAGNOSTICS (LUDHIANA) PRIVATE LIMITED	Wholly Owned Subsidiary
6.	KDPL DIAGNOSTICS (PATIALA) PRIVATE LIMITED	Wholly Owned Subsidiary
7.	KDPL DIAGNOSTICS (SAS NAGAR) PRIVATE LIMITED	Wholly Owned Subsidiary
8.	KRSNAA RETAIL PRIVATE LIMITED	Wholly Owned Subsidiary
9.	APULKI HEALTHCARE KDMC PRIVATE LIMITED	Step down associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We draw attention to Note No. 04 of the consolidated unaudited financial results regarding the additions made by the Income Tax Authorities, on account of Undisclosed income and disallowance of certain deductions claimed by the Holding company, consequent to an assessment order passed and a demand notice issued on the Holding Company for the assessment year ("AY") 2017-18 to AY 2023-24 under search assessment proceedings conducted under section 132(1) and section 133A of the Income Tax Act, 1961.

   The Holding Company has filed appeals with the Joint Commissioner (Appeals) or Commissioner of Income- Tax (Appeals) against the said Orders and has deposited tax under protest amounting to Rs. 102.77 million.

   Further as explained in the note, the management believes that considering the on-going assessment proceedings and the appeals filed by the Holding Company, the impact, if any including income tax, interest and other charges, on the previous period financial statements and the current year consolidated unaudited financial results for the quarter ended June 30, 2026, is not expected to be material.

   Our opinion is not modified in respect of this matter.

7. We did not review the financial information of one (1) subsidiary included in the Statement, whose interim financial information reflects total revenues of INR 181.16 million, total net loss after tax of INR 8.83 million and total comprehensive loss of INR 8.83 million, for the quarter ended June 30,2026, respectively, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of INR 0.05 million and total comprehensive income of INR 0.05 millon for the quarter ended June 30,2026, respectively, whose financial information has not been reviewed by us. These interim financial information has been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary and associate, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

MSKA & ASSOCIATES LLP
Chartered Accountants

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

Yogesh Yewale
Partner
Membership No.: 158877
UDIN:26158877GNIJGB3539

Place: Pune
Date: August 13, 2026

Krsnaa Diagnostics Limited
CIN:L74900PN2010PLC138068

Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Year ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		(Unaudited)	(Audited) (Refer Note 5)	(Unaudited)	(Audited)
1	**Income**				
	Revenue from operations	2,355.32	1,926.04	1,929.78	7,727.74
	Other income	72.40	314.99	39.50	433.90
	Total Income	**2,427.72**	**2,241.03**	**1,969.28**	**8,161.64**
2	**Expenses**				
	Cost of material consumed	501.86	443.74	474.26	1,790.45
	Employee benefits expense	360.59	333.48	355.63	1,404.83
	Finance costs	148.34	120.84	63.00	343.64
	Depreciation and amortization expense	279.55	225.87	216.32	904.61
	Fees to hospitals and others	405.85	143.04	153.65	617.08
	Other expenses	507.22	457.00	432.28	1,796.67
	Total Expenses	**2,203.41**	**1,723.97**	**1,695.14**	**6,857.28**
3	**Profit before share of profit in associate and tax (1) - (2)**	**224.31**	**517.06**	**274.14**	**1,304.36**
4	**Share of profit/(loss) in associate**	**0.05**	**(0.05)**	**0.08**	**(0.69)**
5	**Profit before tax (3) + (4)**	**224.36**	**517.01**	**274.22**	**1,303.67**
6	**Tax expenses**				
	Income Tax charge	57.84	84.58	58.31	245.29
	Income Tax charge relating to earlier year	-	-	-	(1.26)
	Deferred tax charge	1.01	15.25	10.71	45.33
	Total tax expenses	**58.85**	**99.83**	**69.02**	**289.36**
7	**Profit for the period/year (5) - (6)**	**165.51**	**417.18**	**205.20**	**1,014.31**
8	**Other comprehensive income**				
	Items that will not be reclassified subsequently to profit and loss				
	Re-measurement gains / (losses) on defined benefit plans	1.20	1.20	1.88	2.96
	Income tax effect	(0.30)	(0.30)	(0.47)	(0.92)
	Total other comprehensive income/(loss) for the period/year	**0.90**	**0.90**	**1.41**	**2.04**
9	**Total comprehensive income for the period/year (7) + (8)**	**166.41**	**418.08**	**206.61**	**1,016.35**
	Profit for the period/year				
	Attributable to:				
	Equity Holders of the Holding Company	165.51	417.18	205.20	1,014.31
	Non Controlling Interests	-	-	-	-
		165.51	**417.18**	**205.20**	**1,014.31**
	Total other comprehensive income /(loss) for the period/year attributable to:				
	Equity Holders of the Holding Company	0.90	0.90	1.41	2.04
	Non Controlling Interests	-	-	-	-
		0.90	**0.90**	**1.41**	**2.04**
	Total comprehensive income for the period /year attributable to:				
	Equity Holders of the Holding Company	166.41	418.08	206.61	1,016.35
	Non Controlling Interests	-	-	-	-
		166.41	**418.08**	**206.61**	**1,016.35**
10	**Paid-up equity share capital (Face Value of INR 5/- each)**	**162.19**	**162.19**	**162.19**	**162.19**
	Other equity				**9,641.69**
	Earnings per equity share (Not annualised for period):				
	Basic (INR)	5.10	12.86	6.35	31.30
	Diluted (INR)	5.04	12.70	6.25	30.88

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Pune
Date: August 13, 2026

Krsnaa Diagnostics Limited
CIN:L74900PN2010PLC138068

Notes to Unaudited Consolidated Financial Results:

1.These unaudited consolidated financial results ('consolidated financial results') of Krsnaa Diagnostics Limited ('the Holding Company') have been reviewed by the Audit Committee and approved by the Board of Directors on August 13, 2026.

2.The above consolidated financial results have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.

3. The Group's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Group as one operating segment. Accordingly, the Group has single reportable segment and it derives entire revenue from the external customers in India and have entire assets located in India. The group has two major external customers which accounts for 10 per cent or more of groups revenues.

4. Pursuant to search and seizure proceedings conducted under the provisions of section 132(1) and section 133A of the Income Tax Act, 1961 ("the search operations"), the Holding Company received assessment order dated March 31, 2024 for Assessment Year ("AY") AY 22-23. Further, Orders for AY 23-24, AY 21- 22, AY 20-21 and AY 17-18 were received during the year ended March 31, 2025 and assessment orders for AY 2018-19 and AY 2019-20 were received on March 19, 2026 under the Income Tax Act, 1961 ("the Orders").

In the aforesaid Orders, the Income Tax authorities have made additions on account of undisclosed income and disallowance of certain deductions claimed by the Holding Company in the respective income tax returns filed for the relevant AY. Consequentially, it has resulted in a demand order of INR 626.90 million. The Holding Company has filed appeals against the aforesaid assessment Orders before the Joint Commissioner (Appeals)/Commissioner of Income-Tax (Appeals). Against the order for AY 2022-23,the Holding Company has deposited the tax under protest amounting to INR 39.27 million. Further, for the remaining AY's the Holding Company has requested to the Assistant Commissioner of Income Tax to adjust the income tax refunds for AY 2024-25 to the extent of INR 63.50 million against the amounts to be deposited under protest. These appeal applications have been acknowledged by the Commissioner of Income-Tax (Appeals).

The Holding Company has provided the requisite disclosure to the stock exchange with respect to the search operations and receipt of the Orders in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015 (as amended).

The management of the Holding Company, based on available information and underlying evidence and opinion obtained from its tax consultants and experts, it of view that the aforesaid demand orders are not tenable and will not have any material impact on the Group's financial position as of June 30, 2026, and on its performance for the quarter ended on that date.

5. The results include financial results for the quarter ended March 31, 2026 which are the balancing results between audited results in respect of full year ended March 31, 2026 and published year to date results for the nine month period ended December 31, 2025, which were subject to limited review.

6. Previous quarter/period figures have been regrouped/ rearranged wherever considered necessary.

Krsnaa Diagnostics Limited

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Pune
Date: August 13, 2026

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

Floor 6, Building No. 1
Cerebrum IT Park, Kalyani Nagar
Pune 411014, INDIA

Independent Auditor's Review Report on standalone unaudited financial results of Krsnaa Diagnostics Limited for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Krsnaa Diagnostics Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Krsnaa Diagnostics Limited (hereinafter referred to as 'the Company') for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw attention to Note No. 04 of the standalone unaudited financial results regarding the additions made by the Income Tax Authorities, on account of Undisclosed income and disallowance of certain deductions claimed by the company, consequent to an assessment order passed and a demand notice issued on the Company for the assessment year ("AY") 2017-18 to AY 2023-24 under search assessment proceedings conducted under section 132(1) and section 133A of the Income Tax Act, 1961.

   The Company has filed appeals with the Joint Commissioner (Appeals) or Commissioner of Income- Tax (Appeals) against the said Orders and has deposited tax under protest amounting to INR 102.77 million.

   Further as explained in the note, the management believes that considering the on-going assessment proceedings and the appeals filed by the Company, the impact, if any including income tax, interest

MSKA & Associates LLP Chartered Accountants and other charges, on the previous period financial statements and the current period standalone unaudited financial results for the quarter ended June 30, 2026, is not expected to be material.

Our opinion is not modified in respect of this matter.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

Yogesh Yewale
Partner
Membership No.: 158877
UDIN: 26158877RTWPQN3159

Place: Pune
Date: August 13, 2026

Krsnaa Diagnostics Limited
CIN:L74900PN2010PLC138068

Statement of Unudited Standalone Financial Results for the quarter ended June 30, 2026

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Year ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		(Unaudited)	(Audited) (Refer Note 5)	(Unaudited)	(Audited)
1	**Income**				
	Revenue from operations	2,106.61	1,730.18	1,756.15	6,909.47
	Other income	72.09	314.06	39.98	434.12
	Total Income	**2,178.70**	**2,044.24**	**1,796.13**	**7,343.59**
2	**Expenses**				
	Cost of material consumed	484.48	425.43	468.96	1,738.65
	Employee benefits expense	284.51	256.56	284.09	1,095.49
	Finance costs	147.21	118.55	62.46	339.41
	Depreciation and amortization expense	277.04	222.49	215.13	897.58
	Fees to hospitals and others	339.34	99.57	127.10	450.59
	Other expenses	430.96	380.32	375.02	1,498.66
	Total Expenses	**1,963.54**	**1,502.92**	**1,532.76**	**6,020.38**
3	**Profit before tax (1) - (2)**	**215.16**	**541.32**	**263.37**	**1,323.21**
4	**Tax expenses**				
	Income Tax charge	53.51	80.97	56.87	234.22
	Income Tax charge relating to earlier period	-	-	-	(1.26)
	Deferred tax charge/(credit)	3.45	26.53	10.88	63.50
	Total tax expenses	**56.96**	**107.50**	**67.75**	**296.46**
5	**Profit for the period/year (3) - (4)**	**158.20**	**433.82**	**195.62**	**1,026.75**
6	**Other comprehensive income**				
	Items that will not be reclassified subsequently to profit and loss:				
	Re-measurement gains/(loss) on defined benefit plans	(0.15)	(0.04)	1.30	(0.60)
	Income tax effect	0.04	0.01	(0.33)	0.15
	Total other comprehensive income/(loss) for the period/year	**(0.11)**	**(0.03)**	**0.97**	**(0.45)**
7	**Total comprehensive income for the period/year, net of tax (5+6)**	**158.09**	**433.79**	**196.59**	**1,026.30**
8	**Paid-up equity share capital (Face Value of INR. 5/- each)**	**162.19**	**162.19**	**162.19**	**162.19**
	Other equity				**9,756.92**
	Earnings per equity share (Not annualized for quarter):				
	Basic (INR)	4.88	13.37	6.10	31.69
	Diluted (INR)	4.81	13.21	6.00	31.26

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Pune
Date: August 13, 2026

Krsnaa Diagnostics Limited
CIN:L74900PN2010PLC138068

Notes to Unaudited Standalone Financial Results:

1.These standalone unaudited financial results ('financial results') of Krsnaa Diagnostics Limited ('the Company') have been reviewed by the Audit Committee on August 13, 2026 and approved by the Board of Directors at its meeting held on August 13, 2026.

2. The above statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.

3. In accordance with Ind AS 108 'Operating Segments', segment information has been given in the unaudited consolidated financial results of the Company.

4. Pursuant to search and seizure proceedings conducted under the provisions of section 132(1) and section 133A of the Income Tax Act, 1961 ("the search operations"), the Company received assessment order dated March 31, 2024 for Assessment Year ("AY") AY 22-23. Further, Orders for AY 23-24, AY 21- 22, AY 20-21 and AY 17-18 were received during the year ended March 31, 2025 and assessment orders for AY 2018-19 and AY 2019-20 were received on March 19, 2026 under the Income Tax Act, 1961 ("the Orders").

In the aforesaid Orders, the Income Tax authorities have made additions on account of undisclosed income and disallowance of certain deductions claimed by the Company in the respective income tax returns filed for the relevant AY. Consequentially, it has resulted in a demand order of INR 626.90 million. The Company has filed appeals against the aforesaid assessment Orders before the Joint Commissioner (Appeals)/Commissioner of Income- Tax (Appeals). Against the order for AY 2022-23,the Company has deposited the tax under protest amounting to INR 39.27 million. Further, for the remaining AY's the Company has requested to the Assistant Commissioner of Income Tax to adjust the income tax refunds for AY 2024-25 to the extent of INR 63.50 million against the amounts to be deposited under protest. These appeal applications have been acknowledged by the Commissioner of Income-Tax (Appeals).

The Company has provided the requisite disclosure to the stock exchange with respect to the search operations and receipt of the Orders in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015 (as amended).

The management of the Company, based on available information and underlying evidence and opinion obtained from its tax consultants and experts, it of view that the aforesaid demand orders are not tenable and will not have any material impact on the Company's financial position as of June 30, 2026, and on its performance for the quarter ended on that date.

5. The results include financial results for the quarter ended March 31, 2026 which are the balancing results between audited results in respect of full year ended March 31, 2026 and published year to date results for the nine month period ended December 31, 2025, which were subject to limited review.

6. Previous quarter/period figures have been regrouped/rearranged wherever considered necessary.

Krsnaa Diagnostics Limited

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Pune
Date: August 13, 2026

krsnaa DIAGNOSTICS
LET'S DO GOOD...

ANNEXURE -B

Sr. No.	Particulars	Details
1	Type of securities proposed to be issued(viz. equity shares, convertibles)	Warrants, each convertible into / exchangeable for one (1) fully paid-up equity share of face value ₹5/- each ("Warrants" / "Equity Shares").
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential issue on a private placement basis, under Section 62(1)(c) read with Section 42 of the Companies Act, 2013 and Chapter V of the SEBI (ICDR) Regulations, 2018.
3	Total number of securities proposed to be issued or total amount for which the securities will be issued (approximately)	Up to 16,21,000 Warrants. The aggregate amount will be decided on the Relevant Date in accordance with SEBI (ICDR) Regulations, 2018.
4	In case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s):	
a)	Name of Investors	Mr. Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited
b)	Post allotment of securities – outcome of the subscription	The Warrants are proposed to be issued to Mr. Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited. Details of the shareholding of the Proposed Allottees in the Company, prior to and after the Preferential Issue assuming full subscription are as under: Pre-Preferential Issue shareholding percentage of the Proposed Allottees: Mr. Rajendra Mutha – 24.75%; Krsna Diagnostics (Mumbai) Private Limited – 2.36% Post-Allotment of Warrants pursuant to the Preferential Issue (assuming full subscription): Mr. Rajendra Mutha – 23.79%; Krsna Diagnostics (Mumbai) Private Limited – 6.78%
5	Issue Price	The issue price shall be determined as the floor price as on the relevant date in the future as determined in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 or Rs. 565/-, whichever is higher.
6	Number of Investors	2 Investors - Mr. Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited.
7	In case of convertibles -intimation on conversion of securities or on lapse of the tenure of the instrument	Each Warrant will be convertible into, or exchangeable for, 1 (one) fully paid-up equity share of the Company of face value of ₹ 5 (Indian Rupees Five), which may be exercised in one or more tranches during a period of 18 (eighteen) months commencing from the date of allotment of Warrants.